Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Recruiting 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 1

Conditions

Multiple Myeloma 210Recurrence 26Neoplasms, Plasma Cell 15Neoplasms 13Immunoglobulin Light-chain Amyloidosis 13Leukemia, Myeloid, Acute 9Lymphoma, Non-Hodgkin 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Smoldering Multiple Myeloma 5Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 4Hematologic Neoplasms 4Plasmacytoma 3Paraproteinemias 3Myelodysplastic Syndromes 3Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Hematologic Diseases 3Carcinoma, Non-Small-Cell Lung 3Amyloidosis 3Waldenstrom Macroglobulinemia 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Plasmablastic Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Disease 2Corneal Diseases 2Blood Protein Disorders 2

Interventions

Cyclophosphamide 22blinatumomab 18Cytarabine 15fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Lenalidomide 7Dexamethasone 7Methotrexate 6Daunorubicin 6Mercaptopurine 5daratumumab 4Whole-Body Irradiation 4Vincristine 4Melphalan 4Idarubicin 4Etoposide 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Maintenance 3Immunotherapy, Adoptive 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Cladribine 3Asparaginase 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neoplasm, Residual × daratumumab × Clear all
NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

University of Alabama at Birmingham

Phase 2 Recruiting
40 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT07021677 2025-06-15

DARA_T_ALL

Tata Memorial Centre

Phase 2 Recruiting
18 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03537599 2025-05-21

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
4 enrolled 7 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06697483 2024-11-25

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Peking University People's Hospital

Phase NA Recruiting
100 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡